TRAZODONE IS METABOLIZED TO \textit{m}-CHLOROPHENYLPIPERAZINE BY CYP3A4 FROM HUMAN SOURCES

SUSAN ROTZINGER,\textsuperscript{1} JIAN FANG, AND GLEN B. BAKER

Neurochemical Research Unit, Department of Psychiatry and Faculty of Pharmacy and Pharmaceutical Sciences, and Division of Neuroscience, University of Alberta

(Received October 15, 1997; accepted March 2, 1998)

This paper is available online at http://www.dmd.org

ABSTRACT:
The metabolism of the antidepressant drug trazodone to its active metabolite, \textit{m}-chlorophenylpiperazine (mCPP), was studied \textit{in vitro} using human liver microsomal preparations and cDNA-expressed human cytochrome P450 (P450) enzymes. The kinetics of mCPP formation from trazodone were determined, and three \textit{in vitro} experiments were performed to identify the major P450 enzyme involved. Trazodone (100 \textmu M) was incubated with 16 different human liver microsomal preparations characterized for activities of 7 different P450 isoforms. The production of mCPP correlated significantly with activity of cytochrome P450 3A4 (CYP3A4) only. Trazodone (100 \textmu M) was then incubated with microsomes from cells expressing human CYP1A1, CYP1A2, CYP2C8, CYP2C9\textsubscript{arg}, CYP2C9\textsubscript{cys}, CYP2C19, CYP2D6, or CYP3A4. Only incubations with CYP3A4 resulted in mCPP formation. In the third experiment, the CYP3A4 inhibitor ketoconazole was found to inhibit mCPP formation concentration dependently in both human liver microsomes and in microsomes from cells expressing human CYP3A4. The present results indicate that trazodone is a substrate for CYP3A4, that CYP3A4 is a major isoform involved in the production of mCPP from trazodone, and that there is the possibility of drug-drug interactions with trazodone and other substrates, inducers and/or inhibitors of CYP3A4.

Adverse pharmacokinetic drug interactions may occur when drugs that are substrates, inducers and/or inhibitors of the same cytochrome P450 P450\textsubscript{2} enzymes are co-administered, potentially altering the expected rate of metabolism of one or both compounds. The clinical consequences can range from a lack of therapeutic efficacy to severe toxicity and, in extreme cases, fatality. Therefore, it is important to identify the major enzymes involved in the metabolism of a drug so that such interactions can be predicted and avoided.

Trazodone is a triazolopyridine antidepressant drug (fig. 1), which is thought to act through combined 5-HT\textsubscript{2} antagonism and 5-HT reuptake blockade (Haria \textit{et al}., 1994). It is often co-prescribed with other antidepressants as a sleep-inducing agent because of its sedative side effects (Fabre, 1990; Jacobsen, 1990, Nierenberg \textit{et al}., 1994) or as an augmentation strategy (Maes \textit{et al}., 1997). This co-prescription introduces the potential for metabolic drug interactions.

Trazodone is extensively metabolized in the liver by hydroxylation, dealkylation, and \textit{N}-oxidation (Baiocchi \textit{et al}., 1974; Yamato, 1974a). The active metabolite mCPP is formed by \textit{N}-dealkylation of the piperazinyl nitrogen (Melzacka \textit{et al}., 1979; Yamato \textit{et al}., 1974b). The metabolite mCPP is of interest because it has 5-HT\textsubscript{2C} agonistic and 5-HT\textsubscript{2A} antagonistic properties (Conn and Sanders-Bush, 1987; Fiorella \textit{et al}., 1995), as well as behavioral effects that are consistent with 5-HT agonistic properties such as worsening of psychoses in humans and anxiogenesis and anorexia in animals and humans (Kahn and Wetzler, 1991). It has also been suggested by some that mCPP may contribute to the antidepressant efficacy of trazodone (Maes, 1997). Therefore, a drug interaction that alters the production of mCPP could have clinically significant effects.

Current information available on the metabolism of trazodone by

\begin{figure}[h]
\centering
\includegraphics[width=0.5\textwidth]{mCPP.png}
\caption{The chemical structures of trazodone and mCPP.}
\end{figure}
the P450 enzymes comes mainly from drug interaction studies, which provide only suggestive evidence of the enzymes involved and do not examine specific metabolic pathways, whether it is the parent compound or a metabolite causing the interaction or whether the interaction is competitive or non-competitive. For example, thioridazine, a CYP2D6 inhibitor, increases plasma concentrations of both trazodone and mCPP, suggesting that both are substrates for CYP2D6 but providing no information as to which metabolic pathways are involved (Yasui et al., 1995). Plasma levels of trazodone, but not mCPP, are lower in smokers than in non-smokers, suggesting a possible role of the smoking-inducible CYP1A2 in trazodone, but not mCPP, metabolism (Ishida et al., 1995). Carbamazepine, a CYP3A4 inducer and substrate, decreases plasma concentrations of both trazodone and mCPP, but mCPP to a lesser extent (Otani et al., 1996). Clinical interactions between trazodone and fluoxetine have been reported in the form of adverse side effects such as headaches, dizziness, and excessive sedation (Metc and Shader, 1990; Nierenberg et al., 1992), as well as increased plasma levels of trazodone (Ararow et al., 1989; Maes et al., 1997) and mCPP (Maes et al., 1997). However, the causes of the interactions cannot easily be determined, as both fluoxetine and its main metabolite norfluoxetine are inhibitors of both CYP2D6 and CYP3A4 (Crewe et al., 1992; Greenblatt et al., 1996).

A detailed in vitro investigation is thus necessary to identify the individual enzymes involved in the various interactions of trazodone. In particular, the pathway leading to the formation of mCPP from trazodone is of interest given the psychopharmacological effects of this metabolite. Several in vitro methods are routinely used to identify the P450 enzymes involved in the oxidation of compounds (e.g. Guengerich, 1996; Iwatsubo et al., 1997). The current experiments were designed to directly identify the major P450 enzymes involved in the metabolism of trazodone to mCPP using human liver microsomal preparations and cDNA-expressed human P450 enzymes.

Materials and Methods

Chemicals. Trazodone and mCPP were purchased from RBI (Natick, MA) and Sigma (St. Louis, MO), respectively. The HCl salt of the internal standard p-chlorophenylethylamine was synthesized in our laboratory, Pentafluorobenzoyl chloride was purchased from Aldrich (Milwaukee, WI), glass-distilled toluene from BDH (Toronto), and potassium carbonate from Fisher Scientific (Nepean, Ontario). The components of the NADPH-generating system, namely β-nicotinamide adenine dinucleotide phosphate, glucose 6-phosphate, glucose 6-phosphate dehydrogenase, and MgCl2, were all obtained from Sigma. Potassium phosphate monobasic and potassium phosphate dibasic (J.T. Baker) were used to prepare a solution of 0.1 M potassium phosphate buffer (pH 7.4).

Microsomal Preparations. Microsomal preparations from metabolically competent cell lines expressing human CYP1A1, CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 were purchased from Gentest (Woburn, MA).

Human liver microsomes characterized for protein content and enzyme activities were obtained from the International Institute for the Advancement of Medicine (Exton, PA).

Incubation Conditions. The drug metabolism experiments were carried out in a volume of 100 μl in 1.5-mL polystyrene microcentrifuge tubes (Fisher). The incubation medium consisted of 25 μl of potassium phosphate buffer, and 10 μl of the NADPH-generating system [final concentration in 100 μl of 1 mg/ml β-nicotinamide adenine dinucleotide phosphate, 1 mg/ml glucose 6-phosphate, 0.4 U/ml glucose 6-phosphate dehydrogenase, and 0.66 mg/ml MgCl2, in 0.1 M potassium phosphate buffer (pH 7.4)], 10 μl of microsomal enzyme preparation (1.5 mg microsomal protein/ml incubation mixture), 50 μl of trazodone solution in 0.1 M potassium phosphate buffer, and 15 μl 0.1 M potassium phosphate buffer (pH 7.4)]. The tubes were incubated for 10 min at 37°C in a water bath (Fisher Isotemp hot water bath). The incubation time was chosen based on preliminary experiments showing that the formation of mCPP was linear within the first 20 min of incubation time. Following the incubation period, the tubes were placed on ice, and 100 μl of ice-cold 25% potassium carbonate solution was added to terminate metabolism.

Assay Procedure for mCPP. To the basified incubation mixture, 300 μl of double distilled H2O (ddH2O) and 1000 ng of the internal standard (p-chlorophenylethylamine, in 100 μl ddH2O) were added. The incubation mixtures were then transferred to screw cap culture tubes (Fisher, 160 mm × 15 mm), and mCPP was extracted and derivatized by shaking the tubes for 15 min on an Ika Vibrex VX reactor (Janke & Kunkel, Staufen, Germany) with 2 ml of a solution of toluene and pentafluorobenzoyl chloride in a ratio of 100:1. The tubes were then centrifuged at 100g for 5 min in a benchtop centrifuge (Sorvall GLC-2B general laboratory centrifuge, DuPont, Wilmington, DE). The organic phase was pipetted to 100 × 13-mm screw cap culture tubes and taken to dryness in a Savant evaporator (Speed Vac SC 110, Fisher). The residue was reconstituted in 150 μl of toluene for gas chromatographic analysis.

Instrumental Analysis. A 1-μl aliquot of the solution in toluene was injected on a Hewlett-Packard (HP) model 5890 gas chromatograph equipped with a nitrogen-phosphorus detector and linked to an HP 3392A integrator. A 15-m fused silica capillary column (internal diameter of 0.25 mm) coated with a 0.25-μm film thickness of 5% phenylmethyl polysiloxane was used. The carrier gas was helium at a flow rate of 3.5 ml/min, and the make-up gas was helium at a flow rate of 30 ml/min. Hydrogen and air were used at flow rates of 4 and 80 ml/min, respectively. The oven temperature was set at 105°C for an initial time of 0.5 min and was then set to increase at a rate of 12°C/min to a final temperature of 295°C. The injection port temperature was set at 270°C, and the detector temperature was 325°C. All injections were in the splitless mode with a purge off time of 0.5 min.

Determination of the Kinetic Constants for mCPP Formation from Trazodone. The kinetic constants of K_M and V_max were estimated for the formation of mCPP from trazodone by incubating varying concentrations of trazodone (450, 300, 200, 133, 88.89, 59.26, 39.51, 26.34, 17.56, 11.71, 7.80, 5.20, 3.47, 2.31, and 0 μM) with human liver microsomes under the conditions described above. The data were analyzed by iterative nonlinear least squares regression analysis (GraphPad Prism), fitting the data to the equation v = (V_max·S/K_M + S), where v is the reaction velocity corresponding to S, the substrate concentration (trazodone), V_max is the maximal velocity, and K_M is the substrate concentration at which the reaction velocity equals 50% of V_max.

Correlations with P450 Enzyme Activities in a Panel of Human Liver Microsomal Preparations. Trazodone (100 μM final concentration) was incubated with the NADPH-generating system and microsomes prepared from a panel of 16 human livers characterized for their catalytic activity for CYP1A2 (phenacetin O-deethylation), CYP2A6 (cumarin 7-hydroxylation), CYP2C19 (mephentoin 4-hydroxylation), CYP2D6 (dextromethorphan O-demethylation), CYP2E1 (chlorozoxazone 6-hydroxylation), CYP3A4 (6-hydroxylation of [14C]-testosterone), and CYP4A11 (omega-hydroxylation of [14C]-lauric acid). The rate of formation of mCPP was then correlated with the activities of the specific enzymes for each of the 16 human livers (GraphPad Prism).

Incubations with Single Expressed Enzymes. Trazodone (100 μM final concentration, added in a volume of 50 μl) was incubated in the NADPH-generating system (25 μl) potassium phosphate buffer (15 μl), and 10 μl of a microsomal preparation (1 mg microsomal protein/ml incubation mixture) expressing CYP1A1, CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 for 30 min. These incubations were repeated in four separate experiments.

Inhibition with Ketoconazole. The CYP3A4 inhibitor ketoconazole (final concentrations in 100 μl of 6.4, 3.2, 1.6, 0.8, 0.4, 0.2, and 0.0 μM, added in 10 μl of buffer) was pre-incubated for 10 min with 25 μl of the NADPH-generating system, 5 μl of potassium phosphate buffer, and 10 μl of either human liver microsomes (1.5 mg of microsomal protein/ml incubation mixture) or microsomes from cells expressing human CYP3A4 (1 mg of microsomal protein/ml incubation mixture). Trazodone (100 μM final concentration, added in a volume of 50 μl) was then added, and the incubation was continued for a further 10 min. As a control, quinidine, a specific inhibitor of CYP2D6, was also incubated as described for ketoconazole, using concentrations of 6.0, 3.0, 1.5, 0.75, 0.375, and 0 μM. The inhibitions were repeated in three separate experiments.

Results

Kinetic Analyses. Incubations of various concentrations of trazodone with human liver microsomes resulted in a concentration-
dependent formation of mCPP, as shown in fig. 2. The apparent $K_M$ was $311.3 \pm 32.19 \mu M$, and apparent $V_{max}$ was $4.95 \pm 0.29 \text{nmol/min/mg protein}$.

**Correlations with P450 Enzyme Activities in a Panel of Human Liver Microsomal Preparations.** The rate of formation of mCPP showed significant correlation ($r = 0.81$, $p < 0.0001$) with CYP3A4 activity (fig. 3). Correlations with all other P450 enzymes failed to reach significance (CYP1A2, $r = 0.27$, $p = 0.32$; CYP2A6, $r = 0.47$, $p = 0.07$; CYP2C19, $r = 0.16$, $p = 0.55$; CYP2D6, $r = 0.41$, $p = 0.11$; CYP2E1, $r = 0.40$, $p = 0.13$; CYP4A11, $r = 0.33$, $p = 0.21$).

**Incubations with Single Expressed Enzymes.** Trazodone incubations with microsomes from cells expressing only CYP3A4 resulted in mCPP production (0.3903 $\pm$ 0.0631 nmol/min/mg protein, $N = 4$), whereas incubations with microsomes from cells expressing only CYP1A1, CYP1A2, CYP2C8, CYP2C9arg, CYP2C9cys, CYP2C19, or CYP2D6 did not result in detectable mCPP formation.

**Inhibition with Ketoconazole.** The CYP3A4 inhibitor ketoconazole resulted in a concentration-dependent inhibition of mCPP production in microsomes from both human liver and cells expressing human CYP3A4 (fig. 4). Incubations with quinidine did not inhibit mCPP formation (fig. 4).

**Discussion**

The present experiments showed that mCPP production from trazodone is correlated with CYP3A4 activity in human liver microsomes, is formed from incubations with microsomes from cells expressing CYP3A4 only, and is diminished in the presence of an inhibitor of CYP3A4. Taken together, these results indicate strongly that trazodone is a substrate of CYP3A4 and that this P450 enzyme is important in the formation of the metabolite mCPP. Therefore, there is the potential for drug-drug interactions with this drug and other substrates, inhibitors, and/or inducers of CYP3A4.

Plasma levels of trazodone show wide interindividual differences and typically range from about 0.38 to 5.8 $\mu M$ (Vatassery et al., 1997). However, it is not the plasma concentration that is relevant but rather the concentration at the enzyme site, or the hepatic concentration, which is of importance with respect to drug interactions (Harvey and Preskorn, 1995; Preskorn, 1996; von Moltke et al., 1996). Lipophilic drugs partition extensively into the liver, and liver/water partition ratios are typically used to estimate liver drug concentrations (Greenblatt et al., 1996). The hepatic extraction ratio for trazodone is not currently known, but if it is assumed to have a partition ratio similar to the selective serotonin reuptake inhibitors, which are also highly lipophilic and have hepatic extraction ratios of 12 to 26 (Harvey and Preskorn, 1995; Schmider et al., 1996), then hepatic concentrations of trazodone can be expected to range from 60 to 100 $\mu M$ at a plasma concentration of 5 $\mu M$. Therefore, the concentration of trazodone used in the present experiments can be considered to be clinically relevant. Furthermore, as the concentration of 100 $\mu M$ trazodone is within the linear range of metabolite formation, kinetic parameters should be constant and thus are applicable to lower trazodone concentrations (Iwatsubo et al., 1997).
The clinical significance of potential drug interactions with trazodone depends upon several factors. First, it is important to distinguish between interactions resulting from trazodone’s effects on other compounds and interactions resulting from the effects of other compounds on trazodone. When considering the effects of trazodone on other compounds, it is important to note that the present experiments showed that trazodone is a substrate of CYP3A4 and therefore may act as a competitive inhibitor of other CYP3A4 substrates. The consequences of this interaction will depend upon the relative affinities and concentrations of trazodone and the competing drug at the enzyme, as well as the therapeutic index of both drugs. The therapeutic index of the interacting drug is important, as clinically significant interactions with a CYP3A4 substrate with a narrow therapeutic index, such as terfenadine, could result (Wilkinson, 1996).

The second type of interaction that may occur is from the effects of other compounds on trazodone metabolism. Although trazodone has a relatively wide therapeutic index, it does have potentially bothersome or dangerous side effects such as excessive sedation, which could become a problem at higher plasma concentrations (Haria et al., 1994). However, the most important consideration with respect to trazodone metabolism is the ability to maintain therapeutic plasma concentrations. Clinical antidepressant response is significantly correlated with steady-state plasma trazodone concentrations, and a threshold concentration of 650 ng/ml is considered necessary for antidepressant response (Monteleone et al., 1989). Therefore, any factor that results in a lowering of plasma trazodone levels may interfere with the clinical efficacy of the drug. Because CYP3A4 levels vary 5–20-fold between individuals (Wilkinson, 1996) and because CYP3A4 is inhibited and induced by many commonly encountered drugs and environmental compounds (von Moltke et al., 1995; Wilkinson, 1996), it is important to be aware that trazodone is a substrate of CYP3A4 and thus subject to many factors that may alter its plasma concentration. The clinical significance of this potential interaction has already been noted with carbamazepine, a CYP3A4 inducer, which decreased plasma trazodone levels (Otani et al., 1996).

The extent of any interaction with trazodone will of course depend upon individual differences in CYP3A4 activity, as well as plasma levels of both trazodone and the interacting drug. However, as the therapeutic index of the interacting drug is important, as clinically significant interactions with a CYP3A4 substrate with a narrow therapeutic index, such as terfenadine, could result (Wilkinson, 1996).

The quantitative importance of CYP3A4 on the overall disposition of trazodone is not currently known, and such knowledge will depend upon the elucidation of the P450 enzymes involved in trazodone’s other metabolic pathways. However, because approximately 20% of a dose of trazodone is recovered in urine as triazolopropionic acid and its conjugates, which is the other fragment formed when trazodone is N-dealkylated to mCPP (Haria et al., 1994; Yamato et al., 1974a, 1974b), it is reasonable to assume that 20% of the dose is also converted to mCPP. Furthermore, plasma levels of mCPP reach 1–20% those of the parent compound (Otani et al., 1996; Vatassery et al., 1997; Yasui et al., 1995); therefore, CYP3A4 is expected to play a significant role in trazodone’s metabolism.

The present experiments are a direct examination of trazodone metabolism to mCPP by the P450 enzymes and provide evidence that CYP3A4 is a major enzyme responsible for this biotransformation. This finding indicates that the potential for drug-drug interactions exists between trazodone and other substrates or inhibitors of CYP3A4.